Port Delivery System Under Priority Review by FDA

Frequent Eye Injections May Soon Be History Genentech Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) is giving priority review for the company’s Port Delivery System for the treatment of wet age-related macular degeneration (AMD). If approved, PDS will be a first-of-its-kind therapeutic approach, offering people living with wet AMD an alternative [Read More]

Rising Above COVID19 Depression

Prevalence of all forms of depression during the COVID19 pandemic was found to be 20% in a study population of 113,285 individuals.(1) Not unexpectedly, this is higher than the pre-pandemic rate. Compounded with already high levels of depression among those who are socially isolated due to visual impairment (2), this gives cause for increased concern [Read More]

Age-Reversal Diet and Lifestyle Plan May Slow AMD Development

Several studies have identified specific nutrients and healthy behaviors as effective in delaying the development and slowing the progression of age-related diseases like macular degeneration. It has been said that the best cure for age-related macular degeneration (AMD) is to simply stop growing older. Now a pilot study of 43 men ages 50 to 72 [Read More]

New AMD Treatments Coming Soon

Sometimes it seems that retina research moves at a snail’s pace, but science is steadily moving toward those treatments and cures that will keep our eyes healthy. This is an update on four therapeutics just around the corner for treatment of age-related macular degeneration (AMD). Of the hundreds of ongoing clinical trials for both wet [Read More]

Neovascularization May Slow Progression of Geographic Atrophy

Neovascularization, or new blood vessel growth, is a restorative function of the body that assists in healing. When it occurs in the retina, however, it can lead to vision loss. In age-related macular degeneration (AMD) the photoreceptor cells weaken over time. In about 10 to 15 percent of AMD patients, the inflammatory system sends new [Read More]